Eupraxia Pharmaceuticals Files to List on TSX

Posted on February 13, 2021 by Mathieu Litalien

See what founder Dan Kent is investing in right now

Dan is on blossom with over 20,000 Canadian investors sharing insights and real-time trades:

On Thursday, Eupraxia Pharmaceuticals filed its preliminary prospectus as it looks to list on the TSX Index. The company is looking to raise $50M at prices between $9.00-11.00 per share. 

The listing is expected to close on March 4, 2021 and Eupraxia will have 12,426,888 common shares outstanding or 13,176,888 common shares assuming over-allotment option is exercised in full and it prices at the mid-range of expectations ($10.00).

This would give the company a valuation of between $124-$132M and will trade under the symbol EPRX.

Eupraxia is a specialty pharmaceutical company, with a focus on advancing a portfolio of drug candidates in the areas of osteoarthritis, post-surgical pain, anti-infectives, oncology and veterinary medicine.

Eupraxia’s lead product candidate, EP-104IAR, currently in Phase 2 clinical trials, is designed to meet the significant unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA).

According to the company, OA accounts for approximately 80% (US$5.6 billion) of the global US$7.3 billion OA therapeutics market and is currently underserved. 

As is normal for early stage bio-techs, the company doesn't generate any revenue and proceeds will be used to further clinical trials and general expenses. 

There is still a long way to go in terms of seeing EP-104IAR as an approved drug. Here is a quick snapshot of the company's Phase 2 timeline:

Investors will have to be patient with this company. There is still plenty of time left, and this isn't one investors have to go chasing immediately upon open.

Likewise, small cap biotechs are highly volatile and make big moves as news of clinical trial progress is known.


News Release

Eupraxia Pharmaceuticals Inc. Announces Filing of Preliminary Prospectus for Proposed Initial Public Offering


VICTORIA, BC, Feb. 11, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company"), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has filed a preliminary prospectus in connection with a proposed initial public offering (the "Offering") of common shares of the Company (the "Common Shares") for gross proceeds of up to $50,000,000. The Offering will be conducted on a best efforts basis by a syndicate of agents (the "Agents") led by Raymond James Ltd., as lead agent and sole bookrunner, together with BMO Nesbitt Burns Inc. and Canaccord Genuity Corp.

The preliminary prospectus has been filed with the securities commissions in each of the provinces of Canada, except Québec, and contains important information relating to the Company, the Offering and the Common Shares. The preliminary prospectus remains subject to completion or amendment. There will not be any sale or any acceptance of an offer to buy the Common Shares until a receipt for the final prospectus has been issued by the relevant securities commissions in Canada.

A copy of the preliminary prospectus may be obtained under the Company's profile at

No securities regulatory authority has either approved or disapproved of the contents of this press release. The Common Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws. Accordingly, the Common Shares may not be offered or sold, directly or indirectly, in the United States, except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Eupraxia

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.

Eupraxia's lead product candidate, EP-104IAR, is currently in Phase 2 development for the treatment of pain due to osteoarthritis of the knee.

In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.

Notice Regarding Forward-looking Statements and Information:

This news release includes forward-looking statements and forward–looking information within the meaning of Canadian securities laws. Often, but not always, forward–looking information can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements in this press release include statements regarding the Offering, including the successful completion of the Offering and the company obtaining a receipt for a final prospectus, the Company's plans, focus and objectives and the potential of Eupraxia's product candidates. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions and subject to risks and uncertainties. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward–looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including the risk factors set forth in the Company's preliminary prospectus under the heading "Risk Factors". Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward–looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward–looking statement or information can be guaranteed. Except as required by applicable securities laws, forward–looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward–looking statement or information, whether as a result of new information, future events or otherwise.

SOURCE Eupraxia Pharmaceuticals Inc.

For further information: For media inquiries, please contact: Vik Peck, Eupraxia Pharmaceuticals Inc., 250.590.3968 ext. 508,; For investor inquiries, please contact: Adam Peeler, on behalf of: Eupraxia Pharmaceuticals Inc., 416.427.1235,

See what founder Dan Kent is investing in right now

Dan is on blossom with over 20,000 Canadian investors sharing insights and real-time trades:

Disclaimer: The writer of this article or employees of Stocktrades Ltd may have positions in securities listed in this article. Stocktrades Ltd may also be compensated via affiliate links in this post. Stocktrades Ltd will run advertisements on our posts. These advertisements do not represent an endorsement by us.

Mathieu Litalien

About the author

Mathieu is an individual investor and has been investing part-time for the better part of the past 20 years. He is primarily interested in fundamental analysis, focusing on the long-term and his portfolio is composed primarily of dividend-paying equities. Mathieu has a moderate risk profile and also looks for growth and value. His passion for finance and the markets have led him to his MBA and writing for Seeking Alpha and Stocktrades. Mathieu also focuses primarily on stock research and content production for Premium and the Stocktrades blog.